| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.18 | 4e-07 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.23 | 8e-07 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.17 | 9e-07 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-06 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | 0.16 | 8e-06 |
| mRNA | tretinoin:carboplatin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.16 | 8e-06 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.16 | 8e-06 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-05 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-05 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | 0.21 | 4e-05 |